[go: up one dir, main page]

NI201500096A - Compuesto químicos - Google Patents

Compuesto químicos

Info

Publication number
NI201500096A
NI201500096A NI201500096A NI201500096A NI201500096A NI 201500096 A NI201500096 A NI 201500096A NI 201500096 A NI201500096 A NI 201500096A NI 201500096 A NI201500096 A NI 201500096A NI 201500096 A NI201500096 A NI 201500096A
Authority
NI
Nicaragua
Prior art keywords
chemical compounds
compounds
processes
formula
preparation
Prior art date
Application number
NI201500096A
Other languages
English (en)
Inventor
Christophe Barlaam Bernard
Berry David
Delouvrie Benedicte
Steven Harris Craig
Marie Paul Lambert - Van Der Brempt Christine
Ouvry Gilles
Patrick Reid Gary
Peter Tomkinson Gary
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201500096A publication Critical patent/NI201500096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con compuestos de Fórmula (I) o sales farmacéuticamente aceptables de los mismos, en donde R1 y R2 tienen cualquiera de los significados definidos anteriormente en la presente en la descripción; procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en el tratamiento de trastornos proliferativos celulares.
NI201500096A 2013-01-23 2015-07-22 Compuesto químicos NI201500096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13305078 2013-01-23

Publications (1)

Publication Number Publication Date
NI201500096A true NI201500096A (es) 2016-02-16

Family

ID=47623992

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500096A NI201500096A (es) 2013-01-23 2015-07-22 Compuesto químicos

Country Status (26)

Country Link
US (2) US9156831B2 (es)
EP (1) EP2948447B1 (es)
JP (1) JP6307096B2 (es)
KR (1) KR102202516B1 (es)
CN (1) CN104936953B (es)
AP (1) AP2015008604A0 (es)
AR (1) AR094553A1 (es)
AU (1) AU2014208964B2 (es)
BR (1) BR112015017331B1 (es)
CA (1) CA2897279C (es)
CL (1) CL2015002027A1 (es)
CR (1) CR20150367A (es)
DO (1) DOP2015000170A (es)
ES (1) ES2608395T3 (es)
IL (1) IL239890A0 (es)
MA (1) MA38287B1 (es)
MX (1) MX361136B (es)
NI (1) NI201500096A (es)
PE (1) PE20151979A1 (es)
PH (1) PH12015501584A1 (es)
RU (1) RU2644769C2 (es)
SG (1) SG11201505631PA (es)
TN (1) TN2015000313A1 (es)
TW (1) TWI606047B (es)
UY (1) UY35275A (es)
WO (1) WO2014114928A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN107137405A (zh) * 2017-04-14 2017-09-08 黄德莲 一种治疗肾炎的药物组合物
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑-羧酸酯类衍生物在医药领域的应用
US12152020B2 (en) 2018-11-05 2024-11-26 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
JP2022506508A (ja) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
ES2953140T3 (es) 2019-03-08 2023-11-08 Syngenta Crop Protection Ag Compuestos de azol-amida activos de manera plaguicida
BR112021018495A2 (pt) 2019-03-20 2021-11-30 Syngenta Crop Protection Ag Compostos de azolamida ativos em termos pesticidas
EP3941914A1 (en) 2019-03-22 2022-01-26 Syngenta Crop Protection AG N-[1-(5-bromo-2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-2-cyclopropyl-6-(trifluoromethyl)pyridine-4-carboxamide derivatives and related compounds as insecticides
CN115443128A (zh) 2020-04-24 2022-12-06 阿斯利康(瑞典)有限公司 药物配制品
CN114788829B (zh) * 2021-01-25 2023-06-20 广州嘉越医药科技有限公司 一种吡啶并[1,2-a]嘧啶酮类似物的应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (es) 1970-09-25 1972-03-28
US4256887A (en) 1978-04-06 1981-03-17 Merck & Co., Inc. 1,2,4-Triazoles and a method for their preparation
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP3028168B2 (ja) 1993-03-29 2000-04-04 住化ファインケム株式会社 ベンゼンスルホンアミド誘導体の製造方法
US5656416A (en) 1994-12-22 1997-08-12 Eastman Kodak Company Photographic processing composition and method using organic catalyst for peroxide bleaching agent
PL184490B1 (pl) 1995-02-02 2002-11-29 Smithkline Beecham Plc Nowe pochodne indolu jako antagonista receptora T
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
JP2000515851A (ja) 1996-07-25 2000-11-28 メルク シヤープ エンド ドーム リミテツド ＧＡＢＡ▲下Ａα５▼レセプターサブタイプの逆アゴニストとしての置換のあるトリアゾロピリダジン誘導体
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
WO2002006271A1 (en) 2000-07-19 2002-01-24 F. Hoffmann-La Roche Ag Pyrimidine derivatives
AU2002343557A1 (en) 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Substituted aryl 1,4-pyrazine derivatives
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
EP1467986A1 (en) 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
GB0306097D0 (en) 2003-03-15 2003-04-23 Elam T Ltd Electroluminescent complexes
US7459454B2 (en) 2003-03-21 2008-12-02 Smithkline Beecham Corporation Aminopyrazine derivatives and compositions
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
AU2005252160A1 (en) 2004-04-13 2005-12-22 Astellas Pharma Inc. Polycyclic pyrazines as potassium ion channel modulators
JP2006028056A (ja) 2004-07-14 2006-02-02 Agro Kanesho Co Ltd ピリミジン誘導体及びこれを含む有害生物防除剤
ES2325865T3 (es) 2004-07-26 2009-09-22 Eli Lilly And Company Derivados de oxazol como agentes receptores de histamina h3, preparacion y usos terapeuticos.
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN101242834A (zh) 2004-12-15 2008-08-13 默克公司 Akt活性抑制剂
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
WO2006135627A2 (en) 2005-06-10 2006-12-21 Merck & Co., Inc. Inhibitors of akt activity
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
ES2336625T3 (es) 2006-03-22 2010-04-14 Vertex Pharmaceuticals Incorporated Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
US10336757B2 (en) 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
PE20080405A1 (es) 2006-07-21 2008-06-18 Irm Llc COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb
NZ575672A (en) 2006-08-23 2011-10-28 Kudos Pharm Ltd 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
JP5206993B2 (ja) 2007-03-07 2013-06-12 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
SI2188291T1 (sl) 2007-08-14 2013-01-31 Bayer Intellectual Property Gmbh Zliti biciklični pirimidini
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
JP4705695B2 (ja) 2007-10-11 2011-06-22 アストラゼネカ アクチボラグ プロテインキナーゼｂ阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
KR20100089090A (ko) 2007-10-25 2010-08-11 아스트라제네카 아베 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
WO2009072621A1 (ja) 2007-12-07 2009-06-11 Nissan Chemical Industries, Ltd. 置換ジヒドロアゾール化合物及び有害生物防除剤
JP2011506563A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー ビスチアゾール誘導体、その製造方法および医薬品としてのその使用
US20110150833A1 (en) 2007-12-21 2011-06-23 The Scripps Research Institute Benzopyrans and analogs as rho kinase inhibitors
WO2009157880A1 (en) * 2008-06-27 2009-12-30 S*Bio Pte Ltd Pyrazine substituted purines
BRPI0918496A2 (pt) 2008-09-02 2019-09-24 Novartis Ag composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula
JP2010083883A (ja) 2008-09-08 2010-04-15 Nissan Chem Ind Ltd イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP2010063863A (ja) 2008-09-11 2010-03-25 Mugen:Kk ヘッドのフェース部背面に音響振動の異なるパイプまたは平板を複数設けた打点位置表示型ゴルフ練習用クラブとその製法
CN101676271B (zh) 2008-09-17 2011-12-14 山东轩竹医药科技有限公司 含有不饱和杂环胺的四环素衍生物
WO2010054398A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR20110082569A (ko) * 2008-11-14 2011-07-19 바이엘 쉐링 파마 악티엔게젤샤프트 Ｈｉｆ 억제제로서의 헤테로시클릭 치환된 아릴 화합물
CA3013000C (en) * 2008-12-19 2022-12-13 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
CA2752105C (en) 2009-02-13 2017-10-31 Matthias Vennemann Fused pyrimidines
CA2752114C (en) * 2009-02-13 2017-06-20 Bayer Pharma Aktiengesellschaft Fused pyrimidines as akt inhibitors
JP2012520868A (ja) 2009-03-20 2012-09-10 ファイザー・インク ３−オキサ−７−アザビシクロ［３．３．１］ノナン
GB0909441D0 (en) 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EP2470021B1 (en) 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
MX2012004020A (es) 2009-10-20 2012-05-08 Cellzome Ltd Analogos de heterociclilo pirazolopirimidina como inhibidores de jak.
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
ES2627703T3 (es) 2010-01-22 2017-07-31 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Inhibidores de PI3·quinasa
EA201201081A1 (ru) 2010-02-05 2013-03-29 Мерк Патент Гмбх Производные гетарил[1,8]нафтиридина
JP2011178673A (ja) 2010-02-26 2011-09-15 Nissan Chem Ind Ltd 非農園芸害虫の防除方法
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
US9346807B2 (en) * 2010-09-14 2016-05-24 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
NZ607527A (en) * 2010-09-16 2015-04-24 Hutchison Medipharma Ltd Fused heteroaryls and their uses
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CN102718745A (zh) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
WO2012162635A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
WO2013049591A2 (en) 2011-09-29 2013-04-04 Verseon Corporation Dual inhibitor compounds and methods of use thereof
HK1205028A1 (en) 2012-04-05 2015-12-11 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of atr kinase and combination therapies thereof

Also Published As

Publication number Publication date
BR112015017331B1 (pt) 2022-01-11
AP2015008604A0 (en) 2015-07-31
PH12015501584A1 (en) 2015-10-05
IL239890A0 (en) 2015-08-31
CN104936953B (zh) 2017-03-08
ES2608395T3 (es) 2017-04-10
AU2014208964B2 (en) 2016-09-01
US9156831B2 (en) 2015-10-13
US20140206700A1 (en) 2014-07-24
BR112015017331A8 (pt) 2019-11-12
PE20151979A1 (es) 2016-01-15
CA2897279A1 (en) 2014-07-31
US20160137634A1 (en) 2016-05-19
TWI606047B (zh) 2017-11-21
BR112015017331A2 (pt) 2017-07-11
US9657008B2 (en) 2017-05-23
UY35275A (es) 2014-07-31
KR20150109385A (ko) 2015-10-01
JP2016508484A (ja) 2016-03-22
AU2014208964A1 (en) 2015-08-06
MX361136B (es) 2018-11-28
EP2948447B1 (en) 2016-09-21
HK1214592A1 (en) 2016-07-29
CA2897279C (en) 2020-12-29
AR094553A1 (es) 2015-08-12
DOP2015000170A (es) 2015-08-16
TW201522329A (zh) 2015-06-16
TN2015000313A1 (en) 2017-01-03
MA38287A1 (fr) 2018-01-31
CR20150367A (es) 2015-10-20
RU2015132370A (ru) 2017-03-02
CN104936953A (zh) 2015-09-23
MA38287B1 (fr) 2018-08-31
RU2644769C2 (ru) 2018-02-14
WO2014114928A1 (en) 2014-07-31
CL2015002027A1 (es) 2015-11-13
JP6307096B2 (ja) 2018-04-04
MX2015009465A (es) 2015-09-28
EP2948447A1 (en) 2015-12-02
KR102202516B1 (ko) 2021-01-12
SG11201505631PA (en) 2015-08-28

Similar Documents

Publication Publication Date Title
NI201500167A (es) Compuestos químicos
NI201500096A (es) Compuesto químicos
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
UY36285A (es) Compuestos que inhiben la proteína mcl-1
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CR20150326A (es) Inhibidores de autotaxina
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
ECSP14013215A (es) Compuestos novedosos
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
ECSP16074478A (es) Compuestos novedosos
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
MX2016006509A (es) Compuestos triciclicos de piperidina.
GT201500189A (es) Inhibidores de autotaxina
CU20150048A7 (es) Compuestos heteroaromáticos como ligandos d1 de dopamina